Sign up to our newsletter for 20% OFF

Research Guides

Best Metabolic Peptides for Research (2026)

By NUPEPS Research TeamNovember 16, 2026

Best Metabolic Peptides for Research (2026)

The metabolic research compounds with the deepest published evidence records are the triple agonist retatrutide and the dual agonist tirzepatide, each anchored by a landmark New England Journal of Medicine trial, followed by the amylin analog cagrilintide, the growth hormone-releasing hormone analog tesamorelin, the mitochondrial-derived peptide MOTS-c, and the small molecule 5-Amino-1MQ. The ranking criterion is depth of published evidence, not promised effect.

That criterion produces a steep evidence gradient: the top entries rest on randomized trials enrolling thousands, while the bottom entries rest on mouse and cell work with no controlled human trial at all. This guide compares their targets and trial histories in one table and explains how a laboratory verifies each material.

How Were These Compounds Selected and Ranked?

The ranking asks one question: how much published evidence, of what quality, exists for a laboratory choosing a metabolic research compound? Large randomized human trials weigh most, then smaller or earlier-phase human trials, then observational human data, then animal and cell studies. Popularity and testimonials were excluded.

Only compounds in the NUPEPS PEPTIDES research catalog are listed, and only compounds whose primary literature is metabolic research: energy balance, adipose biology, insulin signaling, or appetite regulation. Five of the six are peptides; the sixth is a small molecule whose different chemistry is stated wherever it appears.

The Six Compounds at a Glance

RankCompoundClassReceptors or targetEvidence depthResearch status
1RetatrutideTriple incretin agonist peptideGIP, GLP-1 and glucagon receptorsPhase 2 randomized trial in NEJM 2023 (n=338); phase 3 program under wayInvestigational; not approved anywhere
2TirzepatideDual incretin agonist peptideGIP and GLP-1 receptorsPhase 3 SURMOUNT-1 trial in NEJM 2022 (n=2,539) plus a full phase 3 programApproved as a prescription medicine; research material is not the approved drug
3CagrilintideLong-acting amylin analog peptideAmylin and calcitonin receptorsPhase 2 trial in The Lancet 2021 (n=706); phase 3 data as the CagriSema combinationInvestigational; not approved anywhere
4TesamorelinGHRH analog peptideGHRH receptorPhase 3 randomized trials in a defined clinical population; regulatory approval in 2010 for a specific pharmaceutical productApproved pharmaceutical product exists for one narrow indication; research material is distinct
5MOTS-cMitochondrial-derived peptideFolate–purine pathway and AMPK signalingLandmark 2015 discovery paper; mostly preclinical work plus observational human dataResearch compound only; no controlled human intervention trial
65-Amino-1MQSmall molecule — not a peptideNNMT enzyme inhibitionPreclinical only: cell and diet-induced-obesity mouse studies from 2017–2018 onwardResearch compound only; no human trial published

Read as a set, the table shows why a single ranking needs its criterion stated. The incretin agonists dominate on trial size, tesamorelin's record is deep but confined to one population, and the last two entries are mechanistic compounds valued for the pathways they open.

1. Retatrutide — What Does the Research Record Show?

Retatrutide, development code LY3437943, is a single peptide that activates three receptors at once: the GIP receptor, the GLP-1 receptor, and the glucagon receptor. Adding glucagon-receptor agonism is the design's defining idea, because glucagon signaling is associated in the literature with energy expenditure and hepatic fat metabolism.

Its anchor publication is the phase 2 trial reported by Jastreboff and colleagues in the New England Journal of Medicine in 2023. In 338 adults with obesity, the least-squares mean change in body weight at 48 weeks was −24.2 percent in the highest-dose group, compared with −2.1 percent on placebo. A phase 3 program is under way, and the compound remains investigational and unapproved. NP-III (RT) is NUPEPS PEPTIDES's product designation for a research reference material containing GLP-3RT. Our retatrutide research guide reviews the record in full, and our tirzepatide vs retatrutide comparison sets the two agonists side by side.

Citation: Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023. PMID: 37366315. DOI: 10.1056/NEJMoa2301972.

2. Tirzepatide — What Does the Research Record Show?

Tirzepatide, development code LY3298176, is a 39-amino-acid peptide that activates two receptors, GIP and GLP-1, and the first dual incretin agonist to complete a full phase 3 program. Its record is the largest here by enrollment: the SURMOUNT and SURPASS programs randomized many thousands of participants.

The anchor publication is SURMOUNT-1, reported in the New England Journal of Medicine in 2022. In 2,539 adults with obesity without diabetes, mean body weight change at 72 weeks was −20.9 percent at the highest studied dose, compared with −3.1 percent on placebo. Tirzepatide is FDA-approved as a prescription medicine. That approval belongs to the regulated pharmaceutical product: the research material is NOT the approved drug, and the two must not be confused. NP-II (TRZ) is NUPEPS PEPTIDES's product designation for a research reference material containing GLP-II (TRZ). The head-to-head context is covered in our tirzepatide vs retatrutide comparison.

Citation: Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022. PMID: 35658024. DOI: 10.1056/NEJMoa2206038.

3. Cagrilintide — What Does the Research Record Show?

Cagrilintide, development code AM833, is a long-acting analog of amylin, the hormone co-released with insulin after meals. Native amylin is cleared within minutes; cagrilintide was engineered so a single molecule circulates for about a week, acting at amylin and calcitonin receptors involved in satiety signaling. It is the only entry built on the amylin pathway.

Its standalone anchor is the phase 2 trial by Lau and colleagues in The Lancet in 2021: in 706 participants, mean weight reductions at 26 weeks ranged from 6.0 to 10.8 percent across doses, versus 3.0 percent on placebo. The phase 3 record belongs mainly to CagriSema, its combination with semaglutide: in REDEFINE 1 (2025), CagriSema produced a mean weight change of −20.4 percent versus −3.0 percent on placebo at 68 weeks in 3,417 adults. Cagrilintide remains investigational. Our cagrilintide research guide covers both trial tiers.

Citation: Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a dose-finding phase 2 trial. The Lancet. 2021. PMID: 34798060. DOI: 10.1016/S0140-6736(21)01751-7. See also Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). New England Journal of Medicine. 2025. PMID: 40544433.

4. Tesamorelin — What Does the Research Record Show?

Tesamorelin is a 44-amino-acid analog of growth hormone-releasing hormone, preserving the full native sequence with a trans-3-hexenoyl group at its N-terminus to slow breakdown. It acts at the GHRH receptor, signaling the pituitary to release its own growth hormone — a different pathway from every incretin compound above it.

Its pivotal trial, reported by Falutz and colleagues in the New England Journal of Medicine in 2007, randomized 412 adults with HIV and excess abdominal fat: visceral adipose tissue fell by 15.2 percent on tesamorelin and rose by 5.0 percent on placebo over 26 weeks. A pharmaceutical tesamorelin formulation was FDA-approved in 2010 for HIV-associated lipodystrophy. That approval covers the regulated product and that population only; research-grade tesamorelin is a distinct laboratory material. Our tesamorelin research guide reviews the full program.

Citation: Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007. PMID: 18057338.

5. MOTS-c — What Does the Research Record Show?

MOTS-c is a 16-amino-acid peptide encoded not in nuclear DNA but in a short open reading frame inside the mitochondrial 12S rRNA gene. Lee and colleagues reported it in Cell Metabolism in 2015, showing that it acts through the folate–purine pathway to activate AMPK, a central cellular energy sensor, and that in mouse models it influenced insulin sensitivity and diet-induced weight gain.

That paper remains the field's foundation, and its limits define this ranking position. The subsequent literature is mostly preclinical, plus observational human work, including a 2021 Nature Communications study of endogenous MOTS-c, exercise, and aging. No controlled trial has administered MOTS-c to human participants, so there is no human efficacy or safety record to rank. Our MOTS-c research guide separates the mouse data from the human observations.

Citation: Lee C, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metabolism. 2015. PMID: 25738459. DOI: 10.1016/j.cmet.2015.02.009. See also Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021. PMID: 33473109.

6. 5-Amino-1MQ — What Does the Research Record Show?

5-Amino-1MQ is not a peptide. It is a small molecule, 5-amino-1-methylquinolinium, that inhibits nicotinamide N-methyltransferase, or NNMT, an enzyme expressed in adipose tissue and liver that consumes NAD+ precursors. It appears in this listicle for one stated reason: it is catalogued and studied alongside the metabolic peptides, in the same adipose-energy research programs, despite its different chemistry.

Its evidence base is the shallowest of the six. Neelakantan and colleagues reported in 2017–2018 that selective NNMT inhibitors reduced body weight, white adipose mass, and adipocyte size in diet-induced obese mice, alongside cell studies of lipogenesis and NAD+ metabolism. No human trial has been published, and nothing about effect or safety in people can be inferred from the mouse record. Our 5-Amino-1MQ research guide reviews the NNMT literature.

Citation: Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018. PMID: 29155147.

How Do the Six Compare Mechanistically?

Four distinct strategies explain the list. The incretin agonists multiply hormone-receptor signals: two receptors for tirzepatide, three for retatrutide. Cagrilintide restores a satiety signal, amylin, that the incretins do not carry. Tesamorelin works upstream of metabolism entirely, through growth-hormone release. MOTS-c and 5-Amino-1MQ work inside the cell, on energy-sensing and NAD+-linked pathways — AMPK activation in one case, NNMT inhibition in the other.

The mechanistic spread is why cross-compound effect comparisons mislead. The trial figures above come from different populations, durations, and designs — 26 to 72 weeks — and no published trial tests two entries on this list head-to-head. The ranking compares evidence depth, which the record supports, rather than effect size across unlike trials.

What Does the Evidence Not Show?

No compound on this list has been shown, in controlled trials in healthy people, to be safe or effective for general weight management outside the specific populations its trials enrolled. The two approved pharmaceutical histories here, tirzepatide and tesamorelin, belong to regulated products and defined indications. Retatrutide and cagrilintide remain investigational, and MOTS-c and 5-Amino-1MQ have no controlled human intervention data at all.

All six materials are supplied by NUPEPS PEPTIDES strictly as research chemicals for laboratory and in vitro use. This listicle is a map of where published work exists and how deep it runs — the only ranking the evidence supports.

How Do Researchers Verify Metabolic Research Material?

Verification follows the same standard as every research peptide. Mass spectrometry confirms molecular identity against the expected weight — a check with real separating power here, where entries range from a 16-amino-acid peptide to 44-amino-acid analogs, and 5-Amino-1MQ's small-molecule mass sits far below them all. Reversed-phase HPLC quantifies purity against synthesis-related impurities.

NUPEPS PEPTIDES publishes batch Certificates of Analysis for its research materials, available at nupeps.com/coas. NUPEPS PEPTIDES tests every batch for purity, quantity, and sterility. For the designated incretin materials, the batch record is also what ties a vial to its designation — NP-III (RT) or NP-II (TRZ) — so the designation on the label and the identity on the certificate should always match.

Frequently Asked Questions

What is the best-studied metabolic peptide?

By enrollment and regulatory history, tirzepatide: a full phase 3 program anchored by SURMOUNT-1 in 2,539 adults, and an FDA approval held by the regulated pharmaceutical product. Retatrutide's phase 2 result is the largest single weight change in this list, but its program is earlier and it remains unapproved.

Why is retatrutide ranked first if tirzepatide is approved?

The ranking weighs the published record as a research map: retatrutide pairs a landmark phase 2 trial with an active phase 3 program and the broadest receptor pharmacology in the class. Approval status is stated for every entry, and tirzepatide's approval is the strongest regulatory record here — it belongs to the pharmaceutical product, not to research material.

Is 5-Amino-1MQ a peptide?

No. 5-Amino-1MQ is a small molecule, 5-amino-1-methylquinolinium, that inhibits the enzyme NNMT. It has no amino-acid sequence. It is included in this listicle because it is catalogued and studied alongside metabolic peptides, and its evidence is preclinical only, from cell and mouse studies, with no published human trial.

Are any of these compounds approved medicines?

Two pharmaceutical products in this history are approved: tirzepatide as a prescription medicine, and a tesamorelin formulation approved in 2010 for HIV-associated lipodystrophy. Retatrutide and cagrilintide are investigational, and MOTS-c and 5-Amino-1MQ are research compounds only. Research materials supplied by NUPEPS PEPTIDES are not the approved drugs and are for laboratory use only.

How can a researcher check metabolic compound quality before an experiment?

Ask for the batch-specific Certificate of Analysis and check mass spectrometry identity against the expected molecular weight for the named compound, plus HPLC purity for the batch actually supplied. NUPEPS PEPTIDES publishes its batch certificates at nupeps.com/coas, covering purity, quantity, and sterility testing.

Conclusion

Ranked by published evidence, metabolic peptide research has a clear shape: two incretin agonists with landmark trials at the top, an amylin analog and a GHRH analog with narrower human records behind them, and two intracellular-pathway compounds whose records are preclinical. The evidence gradient from top to bottom is the most important fact in the list.

Whichever compound a study calls for, the sourcing standard is the same: identity confirmed by mass spectrometry, purity verified by HPLC, and a Certificate of Analysis issued for the specific batch in hand. This article is educational material about research compounds and is not medical advice.

Frequently asked questions

Is Best Metabolic Peptides for Research (2026) for human use?

No. All compounds discussed in this guide are strictly for laboratory research use only. Not for human or veterinary use.

Where can I find the Certificate of Analysis?

Certificates of Analysis are available in our COA library. Each batch is third-party tested for purity and identity.

How should research compounds be stored?

Store according to the vial label instructions. Generally, lyophilized compounds should be kept in a cool, dry place away from light. Refer to the specific product documentation for details.

All products are intended strictly for laboratory research and in-vitro use only. Not for human or veterinary consumption, diagnostic, or therapeutic use. Products are not drugs, foods, cosmetics, or dietary supplements and may not be misbranded, misused, or mislabeled.

Related articles